Dai ichi Life Insurance Company Ltd Sells 435 Shares of Illumina, Inc. (NASDAQ:ILMN)

Dai ichi Life Insurance Company Ltd cut its holdings in Illumina, Inc. (NASDAQ:ILMN) by 9.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,131 shares of the life sciences company’s stock after selling 435 shares during the period. Dai ichi Life Insurance Company Ltd’s holdings in Illumina were worth $539,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Tidal Investments LLC raised its holdings in Illumina by 51.2% in the 1st quarter. Tidal Investments LLC now owns 9,901 shares of the life sciences company’s stock worth $1,361,000 after purchasing an additional 3,352 shares during the period. Comerica Bank raised its stake in shares of Illumina by 22.2% in the first quarter. Comerica Bank now owns 32,070 shares of the life sciences company’s stock worth $4,404,000 after buying an additional 5,819 shares during the period. Virtu Financial LLC purchased a new position in shares of Illumina during the 1st quarter valued at about $271,000. Atria Investments Inc grew its stake in shares of Illumina by 72.6% during the 1st quarter. Atria Investments Inc now owns 21,165 shares of the life sciences company’s stock valued at $2,906,000 after acquiring an additional 8,902 shares during the period. Finally, Cetera Investment Advisers increased its holdings in Illumina by 361.1% in the 1st quarter. Cetera Investment Advisers now owns 14,617 shares of the life sciences company’s stock worth $2,007,000 after acquiring an additional 11,447 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on ILMN. Royal Bank of Canada lifted their price target on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. UBS Group upped their target price on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. TD Cowen raised their price target on Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Robert W. Baird upped their price objective on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Finally, StockNews.com began coverage on Illumina in a research note on Thursday, August 29th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $164.00.

Illumina Stock Performance

NASDAQ:ILMN opened at $144.36 on Friday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The stock’s fifty day moving average is $141.62 and its 200 day moving average is $125.66. The firm has a market capitalization of $22.90 billion, a PE ratio of -14.49 and a beta of 1.13. Illumina, Inc. has a fifty-two week low of $93.51 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business’s revenue was down 3.5% on a year-over-year basis. During the same quarter last year, the business earned $0.33 EPS. On average, sell-side analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.